Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Taft Bhuket"'
Publikováno v:
Hepatology Communications, Vol 2, Iss 9, Pp 1147-1155 (2018)
Individuals from the 1945‐1965 birth cohort account for the majority of hepatocellular carcinoma (HCC) cases in the United States. Understanding trends in HCC among this birth cohort is vital given the increasing burden of chronic liver disease amo
Externí odkaz:
https://doaj.org/article/154c1a8913c2437b83ffae4d56e89f0d
Publikováno v:
J Clin Exp Hepatol
BACKGROUND: Direct-acting antivirals (DAAs) are expected to improve outcomes for patients with hepatitis C virus (HCV) infection after liver transplantation (LT). We aim to evaluate trends in post-LT outcomes with availability of DAAs. METHODS: We re
Publikováno v:
Journal of Clinical Gastroenterology. 54:e63-e72
GOAL The goal of this study was to evaluate disparities in hospital outcomes among inflammatory bowel disease (IBD) related hospitalizations in the United States with a focus on ethnicity-specific disparities. BACKGROUND IBD-related hospitalizations
Publikováno v:
Journal of Clinical and Experimental Hepatology. 9:182-190
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) outcomes among Asians may differ by the Asian ethnic subgroup. We aim to evaluate the impact of the Asian ethnic subgroup on HCC tumor stage, treatment received, and overall survival among US adults.
Publikováno v:
Journal of Clinical Gastroenterology. 53:65-70
To evaluate rates and predictors of retention into hepatocellular carcinoma (HCC) surveillance beyond initial screening among underserved cirrhosis patients.Although initial HCC screening among cirrhosis patients remains low, few studies have evaluat
Publikováno v:
Journal of Viral Hepatitis. 26:350-361
Direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection achieve high cure rates, reducing HCV-related disease progression to cirrhosis and hepatocellular carcinoma. We aim to evaluate the impact of DAAs on US liver trans
Publikováno v:
Journal of Clinical and Experimental Hepatology. 8:235-240
BACKGROUND AND AIMS: Delays in diagnosis of chronic hepatitis B virus infection (HBV) may be more common among underserved safety-net populations, contributing to more advanced disease at presentation. We aim to evaluate rates of and predictors of ci
Publikováno v:
Hepatology Communications, Vol 2, Iss 9, Pp 1147-1155 (2018)
Hepatology Communications
Hepatology Communications
Individuals from the 1945-1965 birth cohort account for the majority of hepatocellular carcinoma (HCC) cases in the United States. Understanding trends in HCC among this birth cohort is vital given the increasing burden of chronic liver disease among
Publikováno v:
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 12:5-8
Aims Better understanding risk factors for metabolic syndrome (MetS) will allow early targeted intervention to mitigate long term risk. We aim to determine the disparate impact of each individual MetS component on overall risk of developing MetS, str
Publikováno v:
Clinical Gastroenterology and Hepatology. 17:1909-1911
Successful linkage and retention of newly diagnosed hepatitis B virus (HBV) patients is critical for disease monitoring. Existing studies have demonstrated significant gaps in the HBV care continuum among U.S. veterans1 and have mostly focused on adh